Skip to main content

Response: Sharpe, Goldsmith and Chalder fail to restore confidence in the PACE trial findings

A Correspondence to this article was published on 12 March 2019

A Research article to this article was published on 22 March 2018


In a recent paper, we argued that the conclusions of the PACE trial of chronic fatigue syndrome are problematic because the pre-registered protocol was not adhered to. We showed that when the originally specific outcomes and analyses are used, the evidence for the effectiveness of CBT and graded exercise therapy is weak. In a companion paper to this article, Sharpe, Goldsmith and Chalder dismiss the concerns we raised and maintain that the original conclusions are robust. In this rejoinder, we clarify one misconception in their commentary, and address seven additional arguments they raise in defence of their conclusions. We conclude that none of these arguments is sufficient to justify digressing from the pre-registered trial protocol. Specifically, the PACE authors view the trial protocol as a preliminary plan, subject to honing and improvement as time progresses, whereas we view it as a contract that should not be broken except in extremely unusual circumstances. While the arguments presented by Sharpe and colleagues inspire some interesting reflections on the scientific process, they fail to restore confidence in the PACE trial’s conclusions.

Peer Review reports

Publications from the PACE trial reported that adding cognitive behavioural therapy (CBT) or graded exercise therapy (GET) to basic medical care significantly improved self-rated fatigue and physical function in a cohort of patients with chronic fatigue syndrome, and also increased the likelihood of recovery. [1, 2] However, the published analyses did not adhere to the pre-registered trial protocol. [3] We recently reanalysed a portion of the trial data using the original pre-registered outcome measures. [4] We found that the evidence for the beneficial effects of CBT or GET was weak, and did not reach the threshold of statistical significance after correcting for the number of originally planned comparisons. Neither treatment significantly increased the rate of recovery. We also raised concerns about the trial’s heavy reliance on self-report measures, which introduces a significant source of bias when a trial is not blinded.

In their recent response to our reanalysis, Sharpe, Goldsmith and Chalder ([5]) dismiss the concerns we raised in our paper and maintain that the conclusions of the PACE trial are robust.

Before addressing their arguments, we first clarify one point. The PACE trial also examined a novel behavioural treatment, called adaptive pacing therapy (APT), which did not yield reliably greater improvement than medical care alone. Sharpe et al. appear to believe that we excluded the APT trial arm from our analyses. This was not the case. The omnibus analyses reported in our paper always included the APT arm. We simply chose not to comment any further on those results, because they were not at issue. Our approach is stated clearly in the Methods section:

“All omnibus analyses … included the adaptive pacing therapy group, because it forms part of the trial design.” ([4], p. 4).

Having addressed this misunderstanding, let us consider Sharpe et al.’s seven remaining arguments in defence of the trial’s original conclusions. [5] Many of these were explicitly addressed in our original paper [4], and where this is the case, we refer to the relevant section.

Argument 1: That the changes to the outcome measures were insubstantial, and there is no reason to prefer the original measures to the modified ones

The pre-registered primary outcome measure was whether participants met the specified threshold for improvement in self-reported fatigue and physical function. Several years after trial preregistration, the investigators decided this measure was “hard to interpret” ([6], p. 25). They replaced it with the continuous scores generated by the two original self-report scales, and they also modified the scoring method for the fatigue scale. [5] In addition, they substantially loosened the definition of recovery used in secondary analyses, making it much easier for patients to qualify as recovered. [2] These changes are clearly not insubstantial. Further, as we showed in our paper, all of them resulted in more successful outcomes than would have been obtained using the pre-registered measures. [4]

Sharpe et al. argue that the pre-specified outcome measures are “no more valid” than the modified ones ([5], p. 4). This argument is puzzling. The purpose of pre-registration is to prevent researchers from altering their outcome measures in ways that favour their hypotheses, after they have begun to observe the trial’s progress. Therefore, all other things being equal, measures that are stipulated ahead of time will always trump those formulated after the fact. Sharpe et al. offer the justification that changing the scoring method for the fatigue scale made it “more accurate and sensitive to change” ([5], p. 1). However, they provide no evidence to support this claim.

The concept of pre-registration forms the cornerstone of a good clinical trial, and this is the reason it is so vital to get good statistical advice before the trial begins, especially on matters such as the sensitivity, validity and interpretability of the primary outcome measures. Of course, it is perfectly acceptable to report additional, exploratory analyses that come to mind at a later date, but these should not replace the originally-specified measures.

An additional reason to prefer the pre-registered primary outcomes is that they formed the basis of the power analyses conducted to determine sample size. Given that the trial was estimated to be sufficiently well-powered to detect effects on a binary outcome measure, the failure to observe such effects reliably is of central interest, and should have been highlighted in the trial publications.

With regard to the recovery measure, we previously addressed all of Sharpe et al.’s justifications for altering these in our original paper, and see no need to repeat those arguments here (see [4] p. 8, see also [7, 8]). To summarise, Sharpe et al. “prefer” their modified definition because it generates similar rates of recovery to previous studies, and is also more consistent with “our clinical experience” ([5], p. 6). Clearly, it is not appropriate to loosen the definition of recovery simply because things did not go as expected based on previous studies. Researchers need to be open to the possibility that their results may not align with previous findings, nor with their own preconceptions. That is the whole point of a trial. Otherwise, the enterprise ceases to be genuinely informative, and becomes an exercise in belief confirmation.

Argument 2: That the changes to the outcome measures were acceptable because certain procedures were followed

The various changes were fully detailed in a separate document published in 2013 ([9]), which Sharpe et al. claim was approved by the trial steering and data monitoring committees. They believe that no further justification is required.

For the reasons outlined above, pre-registered primary outcome measures have a special status in science, which is devalued if we allow researchers to alter them without strong justification. Administrative approval by a committee is simply not sufficient. In our paper, we showed that the investigators’ scientific justifications failed to stand up to careful scrutiny (see [4], pp. 7–8). And clearly, a document published in 2013 - two years after the primary results were reported – simply cannot be used as a replacement for the original pre-registered trial protocol.

Argument 3: That our reanalysis was methodologically flawed

Putting aside the erroneous criticism regarding the APT arm, Sharpe and colleagues raised three further criticisms of our reanalysis. The first was that we did not adhere to “an a priori analysis plan” ([5], p. 1). This claim is puzzling, because of course we followed the investigators’ own analysis plan as set out in their trial protocol – or to be precise, we followed it as closely as was possible, given the data we had available. All our decisions were based on the best possible fit to what was stipulated in the protocol, or where no guidance was provided, we referred to other trial publications. All these decisions are fully documented in our paper ([4], p.4).

Second, Sharpe et al. criticise our method of correcting for multiple comparisons, which took into account all six planned comparisons specified in the original trial protocol. They argue that a gentler correction was more appropriate because we were primarily interested in only two comparisons. However, again, our objective was to report the results that would have been obtained if the trial protocol had been adhered to. Since there were six comparisons planned in that protocol, six is the appropriate number to correct for.

Sharpe et al.’s final criticism was that our analysis “only used part of the trial dataset” ([5], p. 1). It is correct that we did not have access to data for several stratification variables (e.g., centre location, therapist). However, we explored the possible impact of these omissions in our paper, concluding that it was likely to be minimal ([4], pp. 4–5). The reason our dataset was so limited was because the PACE investigators had been unwilling to share their data. The (small portion of) data we analysed was made available only after a successful application under the UK Freedom of Information Act. [10]

Sharpe et al. appear to prefer their own, unpublished analysis of the original primary outcome measures, which they conducted in 2016, shortly after they had been directed to release the relevant data. [5]. However, their method of analysis diverged in several substantive ways from the preregistration method. Our analysis is therefore to be preferred.

Argument 4: That the absence of treatment effects at long-term follow-up is of no importance; what matters is that scores did not actually decline

A 2015 paper reported that, at long-term follow-up, there were no longer any significant differences amongst the trial arms. [11] Sharpe et al. dismiss this null result, arguing that additional, optional treatments given after the trial’s conclusion may have obscured any real treatment effects. [5] Instead, they emphasise the fact that numerical scores did not significantly decline between the trial end point and long-term follow-up. There are two problems with this reasoning. The first is that there was no evidence to support the speculation that post-trial therapy obscured genuine group differences (in our paper, we showed that the pattern of results was much the same when participants who received substantial additional post-trial therapy were excluded). Second, in a clinical trial, it is inappropriate to directly compare scores at two timepoints, especially when the number of drop-outs is large (almost a quarter of all participants) and almost certainly non-random. The only defensible conclusion here is that the small self-reported benefits of CBT and GET over the other treatment arms were no longer evident at long-term follow-up.

Argument 5: That there is no reason to be concerned about bias associated with the trial’s reliance of self-report measures

In our paper, we argued that because the PACE trial was non-blinded, and only CBT and GET participants were told their treatments were “effective”, then any self-reported improvements are likely to be biased. Sharpe et al. believe that any such bias would be small, because: a) participants did not just give global ratings, but rather answered specific questions about their fatigue and physical function; and b) other, secondary self-report measures patterned in a similar way. They appear to be unaware that biases can be observed on a wide range of different kinds of self-report measures, including symptom-specific ones, and that they generally operate in the same direction across all types of self-report measures (see [12] for a review and metanalysis). When assessing whether self-reported measures are influenced by bias, we must examine whether they pattern in a similar way to those observed on more objective measures (e.g., estimates of physical fitness, activity levels). However, on the majority of the objective measures examined in the PACE trial, CBT and GET fared no better than the other treatment arms (for discussion, see [4] p. 10).

Sharpe and colleagues also repeat the argument that CBT and GET participants did not have higher expectations than other participants at trial outset. We addressed this argument in our paper, and showed that information provided during CBT and GET would have been likely to significantly heighten those expectations (see [4], p. 9).

Argument 6: That the PACE trial findings are robust, because they are in line with both previous and subsequent trials

Sharpe et al. believe that because the PACE trial’s findings were consistent with other studies examining similar interventions, that this demonstrates their robustness. Of course, convergence with previous findings is not in itself proof of sound methodology. Also, these studies were subject to the same problems as the PACE trial – plus some additional ones - so it is not at all surprising that they also yielded positive outcomes. The majority were not pre-registered, were based on small samples and were problematic in various other ways (e.g. use of a passive control condition, significant loss of participants to follow-up). When we also consider that positive outcomes are more likely to be published than negative ones, then this body of evidence begins to look very problematic indeed.

Criticisms of the trial are based on a principled objection to “psychological” explanations of chronic fatigue syndrome and are therefore invalid

Sharpe and colleagues suggest that objections to the PACE trial findings (including, presumably our critique) may stem from a principled aversion to “psychological” models of CFS. They maintain that the treatments trialled were theory-neutral, and that the trial findings do not speak to the question of illness causation.

The issue of ideological bias is an important one. But before we address it, one point needs clarification. The treatments tested in the PACE trial were not assumption-free. CBT and GET were explicitly based on a behavioural/deconditioning model of CFS, which assumes that there is no underlying disease process ([1]), and that the patient’s thoughts, feelings and behaviours are the primary factors maintaining the illness. The relevant therapy manuals make this position explicit. For example, the CBT participants’ manual tells them that “there is nothing to stop your body from gaining strength and fitness” ([13], p. 31). The GET manual assures patients that increasing activity will not cause any harm ([14], p.79). If PACE’s behavioural/deconditioning model of CFS proved to be unfounded, then these interventions would need to undergo substantial modification – and the trial’s conclusions would not be generalizable to these new interventions.

Turning now to ideology, the PACE trial investigators began work on the trial with the firm belief that thoughts, feelings and behaviours were the central perpetuators of CFS, and that psychological interventions could reverse the illness ([15,16,17,18,19]; see also [20] for discussion). In contrast, we approached our analysis from a more conservative, sceptical perspective: we considered that a false positive conclusion regarding the benefits of CBT and GET could be harmful for patients. For example, it could limit patients’ treatment options and reduce the opportunities for future research into new treatments. Readers can consider the original findings and the reanalysis in the context of these two very different perspectives and draw their own conclusions.


New arguments presented by Sharpe et al. [5] inspire some interesting reflections on the scientific process, but they fail to restore confidence in the PACE trial’s original conclusions. The unjustified optimism surrounding CBT and GET – fuelled by the PACE trial publications – has almost certainly hindered the search for more effective treatments. Patients with this illness suffer terribly and they are desperate for treatments that really work. It is time to turn our attention to other approaches.

In addition, many of the issues discussed above have importance that goes well beyond CBT, GET and even chronic fatigue syndrome. In the field of psychology, there is a growing awareness that some of our scientific practices are problematic, and that serious reform is needed to improve the quality of our evidence base. [21,22,23,24] The current rejoinder touched on several central themes in this methodological debate, including the potential dangers of diverging from a preregistered protocol, the subtle biases introduced by researchers’ own beliefs and allegiances, and also the problems associated with the use of self-report measures. It is likely that the debate concerning the PACE trial will have implications reaching far beyond the illnesses and treatments under investigation.


  1. White PD, Goldsmith KA, Johnson AL, Potts L, et al. Comparison of adaptive pacing therapy, cognitive behaviour therapy, graded exercise therapy, and specialist medical care for chronic fatigue syndrome (PACE): a randomised trial. Lancet. 2011;377(9768):823–36.

    Article  Google Scholar 

  2. White PD, Goldsmith K, Johnson AL, Chalder T, Sharpe M. Recovery from chronic fatigue syndrome after treatments given in the PACE trial. Psychol Med. 2013;43(10):2227–35.

    Article  Google Scholar 

  3. White PD, Sharpe MC, Chalder T, DeCesare JC, Walwyn R. Protocol for the PACE trial: a randomised controlled trial of adaptive pacing, cognitive behaviour therapy, and graded exercise as supplements to standardised specialist medical care versus standardised specialist medical care alone for patients with the chronic fatigue syndrome/myalgic encephalomyelitis or encephalopathy. BMC Neurol. 2007;7:1.

    Article  Google Scholar 

  4. Wilshire CE, Kindlon T, Courtney R, Matthees A, Tuller D, Geraghty K, Levin B. Rethinking the treatment of chronic fatigue syndrome—a reanalysis and evaluation of findings from a recent major trial of graded exercise and CBT. BMC Psychol. 2018;6(1):6.

    Article  Google Scholar 

  5. Sharpe M, Goldsmith KA, Chalder T. The PACE trial of treatments for chronic fatigue syndrome: a response to WILSHIRE et al. BMC Psychol. 2019;7:15.

    Article  Google Scholar 

  6. White PD, Chalder T, Sharpe M. The planning, implementation and publication of a complex intervention trial for chronic fatigue syndrome: the PACE trial. BJPsych Bull. 2015;39(1):24–7.

    Article  Google Scholar 

  7. Wilshire C, Kindlon T, Matthees A, McGrath S. Can patients with chronic fatigue syndrome really recover after graded exercise or cognitive behavioural therapy? A critical commentary and preliminary re-analysis of the PACE trial. Fatigue. 2017;5(1):43–56.

    Google Scholar 

  8. Wilshire C, Kindlon T, McGrath S. PACE trial claims of recovery are not justified by the data: a rejoinder to Sharpe, Chalder, Johnson, goldsmith and white (2017). Fatigue. 2017;5(1):62–7.

    Google Scholar 

  9. Walwyn R, Potts L, McCrone P, Johnson AL, DeCesare JC, Baber H, Goldsmith K, Sharpe M, Chalder T, White PD. A randomised trial of adaptive pacing therapy, cognitive behaviour therapy, graded exercise, and specialist medical care for chronic fatigue syndrome (PACE): statistical analysis plan. Trials. 2013;14(1):386.

    Article  Google Scholar 

  10. Queen Mary University of London (QMUL): Statement: disclosure of PACE trial data under the freedom of information act. 2016. Accessed 22 Mar 2019.

  11. Sharpe M, Goldsmith KA, Johnson AL, Chalder T, Walker J, White PD. Rehabilitative treatments for chronic fatigue syndrome: long-term follow-up from the PACE trial. Lancet Psychiatry. 2015;2(12):1067–74.

    Article  Google Scholar 

  12. Hróbjartsson A, Emanuelsson F, Thomsen AS, Hilden J, Brorson S. Bias due to lack of patient blinding in clinical trials. A systematic review of trials randomizing patients to blind and nonblind sub-studies. Int J Epidemiol. 2014;43(4):1272–83.

    Article  Google Scholar 

  13. Burgess M, Chalder T. PACE manual for participants: cognitive behavioural therapy. 2004. Accessed 22 Mar 2019.

  14. Bavinton J, Dyer N, White PD. PACE manual for participants: graded exercise therapy. 2004. Accessed 22 Mar 2019.

  15. Deale A, Chalder T, Marks I, Wessely S. Cognitive behavior therapy for chronic fatigue syndrome: a randomized controlled trial. Am J Psychiatry. 1997;154:408–14.

    Article  Google Scholar 

  16. Deale A, Chalder T, Wessely S. Illness beliefs and treatment outcome in chronic fatigue syndrome. J Psychosom Res. 1998;45:77–83.

    Article  Google Scholar 

  17. Fulcher KY, White PD. Randomised controlled trial of graded exercise in patients with the chronic fatigue syndrome. BMJ. 1997;314:1647–52.

    Article  Google Scholar 

  18. Sharpe M, Hawton K, Simkin S. Cognitive behaviour therapy for the chronic fatigue syndrome: a randomised controlled trial. BMJ. 1996;312:22–6.

    Article  Google Scholar 

  19. Wessely SC, Hotopf M, Sharpe M. Chronic fatigue and its syndromes. Oxford: Oxford University Press; 1998. p. 428.

    Google Scholar 

  20. Wilshire C. The problem of bias in behavioural intervention studies: lessons from the PACE trial. J Health Psychol. 2017 Aug;22(9):1128–33.

    Article  Google Scholar 

  21. Pashler H, Wagenmakers EJ. Editors’ introduction to the special section on replicability in psychological science: a crisis of confidence? Perspect Psychol Sci. 2012;7(6):528–30.

    Article  Google Scholar 

  22. Ioannidis JP. Why science is not necessarily self-correcting. Perspect Psychol Sci. 2012;7(6):645–54.

    Article  Google Scholar 

  23. Chambers C. The seven deadly sins of psychology: a manifesto for reforming the culture of scientific practice. In: Princeton University Press; 2017.

    Google Scholar 

  24. Hughes BM. Psychology in crisis. In: Macmillan International Higher Education; 2018.

    Google Scholar 

Download references


Not applicable.


None to declare.

Availability of data and materials

Not applicable.

Author information

Authors and Affiliations



CW and TK contributed equally to this response. Both authors read and approved the final manuscript.

Corresponding author

Correspondence to Carolyn E. Wilshire.

Ethics declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

CW and TK are both authors on Wilshire et al. [4]. TK works in a voluntary capacity for the Irish ME/CFS Association.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (, which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Wilshire, C.E., Kindlon, T. Response: Sharpe, Goldsmith and Chalder fail to restore confidence in the PACE trial findings. BMC Psychol 7, 19 (2019).

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: